



## ASX ANNOUNCEMENT

### ***Professor Dao-Yi Yu of Lions Eye Institute appointed to Scientific Advisory Board***

**Perth, Australia; 30 July 2020. NeuroScientific Biopharmaceuticals Ltd ASX: NSB ("NeuroScientific" or "the Company")** is pleased to announce the appointment of Professor Dao-Yi Yu, Head of Physiology and Pharmacology Research, Lions Eye Institute, Perth to the Company's Scientific Advisory Board. Professor Yu leads a world-renowned research team focused on major vision threatening diseases such as glaucoma and retinal vascular disease. His research team was successful in developing several new clinical diagnostics and therapeutics in the ophthalmology field such as a tiny microfistula tube that reduces intraocular pressure that is regulatory approved in the US, Europe and Australia.

Professor Yu's group has long term collaborations with many prestigious universities and leading international medical device and pharmaceutical companies and have developed breakthrough IP and techniques that lead to funding of a successful start-up, AqueSys (acquired by Allergan in 2015 for US\$400M).

Professor Yu has published almost three hundred peer-reviewed publications in prestigious journals and will take a leading role at our Advisory Board to advance NeuroScientific's Glaucoma program into clinical studies.

"We are extremely pleased to have Professor Yu joining our team. It's a big win for our company to have such an esteemed scientist with proven commercial success to help us take our Glaucoma program into the next phase of development," commented Matt Liddelow, CEO and MD of the Company. "NeuroScientific have been working with Professor Yu and his group since 2018 and we were able to produce ground-breaking data in rabbit and pig models of Glaucoma. We are looking forward to achieving more success, including clinical outcomes in this program, under his guidance."

The Company has prepared an educational video demonstrating the science and mechanism of action of EmtinB as a new disease modifying treatment for Glaucoma. Link is available below:

<https://vimeo.com/442599776>

### **About NeuroScientific Biopharmaceuticals Limited**

NeuroScientific Biopharmaceuticals (ASX:NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB. For more information, please visit [www.neuroscientific.com](http://www.neuroscientific.com)

**END**

***Announcement authorised by the Board of Directors of NeuroScientific Biopharmaceuticals***

### **Contacts**

Matthew Liddelow  
CEO and Managing Director  
[ml@neuroscientific.com](mailto:ml@neuroscientific.com)  
+61 8 6382 1805

Brian Leedman  
Non-executive Chairman  
[bl@neuroscientific.com](mailto:bl@neuroscientific.com)  
+61 412 281 780